Pharma Marketing Under UCPMP 2024

India is the world's third-largest pharmaceutical market by volume and the largest generic supplier globally. The domestic formulation market exceeds ₹2 lakh crore and continues to grow at 8-10% annually. Within this market, pharmaceutical marketing — the communication between drug companies, their field force, and healthcare professionals — is one of the largest institutional communication activities in the country.

The UCPMP 2024 update has introduced the most significant framework changes in two decades. For pharma companies, their marketing agencies, and the HCPs who receive promotional inputs, understanding the new framework is both a compliance requirement and a commercial opportunity.

ICG's pharma practice — built on IIT BHU pharmaceutical engineering foundations — has operated within the pharma marketing compliance space since 2018. This is the complete framework for compliant, effective pharma marketing under UCPMP 2024.

HCP-Facing vs Patient-Facing: The Fundamental Divide

Pharma marketing operates across two fundamentally different audiences:

HCP-facing communication (doctors, pharmacists, nurses, hospital procurement teams):

• Governed by UCPMP 2024
• Content: detailed prescribing information, clinical evidence, safety profile, published research
• Channels: field force (MRs), MSLs, CME programmes, medical publications, email

Patient-facing communication (general public):

• Governed by Schedule J + DMRA for prescription products and many OTC categories
• Content: disease awareness (permitted), service framing (permitted), treatment outcome claims (prohibited)
• Channels: consumer media — digital, social, OOH, print

ICG operates across both tracks for pharma clients. The compliance framework is different for each, and the content must be strictly separated. HCP-approved promotional materials must not appear in patient-facing channels.

HCP Engagement Under UCPMP 2024: The New Rules

Medical Representatives (MRs): The field force remains the primary HCP touchpoint for most prescription brands in India. Under UCPMP 2024:

• MRs must carry prescribed credentials at all doctor visits
• Only DGCI-approved promotional content may be shared (no off-label promotion)
• Product samples: permitted within DGCI-approved sample limits, with required documentation
• Adverse event reporting: MRs encountering AEs during calls must formally report through the pharmacovigilance system
• Gifts of any kind: prohibited entirely (including branded items beyond minimal value stationery)

ICG's Pharos RouteIQ module (field force routing intelligence) and RxFlow (prescription tracking analytics) are built to ensure MR compliance tracking and reporting.

CME Sponsorship: Continuing Medical Education sponsorship is the principal permitted form of HCP engagement under UCPMP 2024. The requirements:

• Must be a genuine scientific/educational event
• Organised by a bona fide medical association (not a pharma company or its agency directly)
• Hospitality strictly limited to the event location, of modest value
• Company's involvement must be disclosed in the programme
• Medical advisors who are HCPs must not receive compensation beyond travel and accommodation

ICG designs CME programmes for pharma clients within this framework — identifying genuine medical associations, structuring educational content that meets UCPMP standards, and managing documentation.

Medical Science Liaisons (MSLs): The MSL function — highly qualified scientific communicators who engage KOLs and senior HCPs — sits in a different compliance space from MRs. MSL interactions are scientific exchange, not promotion. UCPMP 2024 draws a clearer line between MSL activities (permitted: scientific data sharing, research collaboration) and promotional activities (governed: MR-driven prescribing support).

ICG's Pharos Scribe supports MSL-facing scientific communication — clinical summaries, evidence reviews, study data presentations — built to the scientific exchange standard.

Digital Channels for HCP Engagement

UCPMP 2024 explicitly includes digital channels. ICG's digital HCP engagement framework:

Email communication: UCPMP-compliant email to verified HCPs (opt-in, with documented consent) for product updates, safety information, CME invitations. Must carry "Promotional Material" disclosure. Must be approved through MLR (Medical-Legal-Regulatory) process before deployment. ICG's Pharos Gate manages this approval workflow.

HCP portals and apps: Gated digital platforms accessible only to verified HCPs — the modern successor to the "closed-circuit" HCP communication model. Content can be more detailed than patient-accessible digital content. Must still comply with UCPMP claim standards and require MLR approval.

Webinars and virtual CME: Post-COVID, virtual CME has become normalised. UCPMP 2024 extends the CME framework to virtual events. Association sponsorship, educational quality, and hospitality limits all apply in the virtual format.

Social media for HCPs: LinkedIn is the primary professional social network for Indian HCPs. Pharma brand presence on LinkedIn for scientific communication is an emerging area. UCPMP 2024 applies — content must be factual, non-promotional in character, or explicitly labelled as promotional material.

Promotional Content and MLR Approval: The Non-Negotiable Process

Every promotional piece — whether print visual aid, video, email, digital banner, or social post — must pass through Medical-Legal-Regulatory review before deployment. This is not UCPMP 2024-specific — it has been standard practice for multinational pharma. The 2024 code makes it explicitly expected for Indian companies as well.

ICG's Pharos Gate manages the digital MLR workflow:

• Content submitted with source references and evidence documentation
• Medical reviewer (company's medical affairs team) signs off on scientific accuracy
• Legal reviewer signs off on claim compliance (UCPMP + Schedule J + applicable law)
• Regulatory reviewer signs off on DGCI-alignment
• Approved content is version-controlled and deployed via Pharos Deploy
• Approved content has an expiry date — after which it must not be used without re-approval

For ICG pharma clients, this process is standard from engagement day 1. It is the infrastructure that protects against the enforcement actions that competitors without MLR workflows face.

ICG's Pharos Platform: The Complete Pharma Marketing Stack

ICG's Pharos platform provides end-to-end pharma marketing operations:

• Pharos Scribe: Scientific writing — MSL-facing summaries, CME content, publication manuscripts
• Pharos Scout: Literature monitoring — tracking new evidence for products and therapy areas
• Pharos Deploy: Campaign deployment and content distribution
• Pharos Vigil: Pharmacovigilance signal monitoring and AE visualisation
• Pharos RxFlow: Prescription analytics — brand performance by geography, specialty, segment
• Pharos RouteIQ: Field force routing and visit planning intelligence
• Pharos Gate: MLR approval workflow
• Pharos Signal: Social listening for brand monitoring and HCP sentiment
• Pharos Pulse: Executive reporting — consolidated pharma marketing intelligence dashboard

ICG works with pharma clients across branded generics, specialty pharmaceuticals, OTC brands, and nutraceuticals. Engagements are typically 18-24 months.

Read next on ICG

• Pharma marketing agency India
• Pharos — pharma intelligence platform
• UCPMP 2024 detailed compliance guide